• 3Q24 oncology sales were $4.0B, +30% YoY, including an $854M contribution from former SGEN products.
• 3Q24 Comirnaty and Paxlovid sales were $1.4B and $2.7B, respectively; both products benefitted from a mid-summer spike in COVID infections.
• 3Q24 GAAP and non-GAAP EPS were $0.78 and $1.06, respectively. (3Q23 GAAP and non-GAAP EPS were losses.)
2024 full-year guidance
• 2024 revenue guidance is now $61-64B, up from the prior guidance of $59.5-62.5B, given three months ago. The $1.5B increase in revenue guidance is due to a $2B increase for Paxlovid (from to $3.5B to $5.5B), and a $500M decrease for all other products, largely due to the withdrawal from the market of Oxbryta.
• 2024 non-GAAP EPS guidance is now $2.75-2.95, up $0.30 at both ends from the guidance given three months. (Both the old and the new guidance ranges include a negative $0.40 hit from SGEN, most of which stems from the net interest expense on the $43B of net debt PFE took on to fund the acquisition.)
• 2024 Comirnaty sales guidance is $5B, unchanged from the guidance three months ago.
Market Data 
Markets 
AI
